Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin for Prophylaxis of Invasive Candidiasis in High-Risk ICU Adults
NCT00099775Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of caspofungin in candidiasis, sponsored by National Cancer Institute. Started Dec 2004; status: completed.
02
Drugs
caspofungin
03
Conditions
candidiasis
Beyond the preview
Go deeper on NCT00099775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099775.